TrialHaematologica2017

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Francesco Zaja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.